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ABSTRACT
Mortality rate is increased in type 2 diabetes (T2D). Low vitamin D levels are 
associated with increased mortality risk in T2D. In the general population, genetic 
variants affecting vitamin D metabolism (DHCR7 rs12785878, CYP2R1 rs10741657, 
GC rs4588) have been associated with serum vitamin D. We studied the association 
of these variants with serum vitamin D in 2163 patients with T2D from the “Sapienza 
University Mortality and Morbidity Event Rate (SUMMER) study in diabetes”. 
Measurements of serum vitamin D were centralised. Genotypes were obtained by 
Eco™ Real-Time PCR. Data were adjusted for gender, age, BMI, HbA1c, T2D therapy 
and sampling season.
DHCR7 rs12785878 (p = 1 x 10–4) and GC rs4588 (p = 1 x 10–6) but not CYP2R1 
rs10741657 (p = 0.31) were significantly associated with vitamin D levels.
One unit of a weighted genotype risk score (GRS) was strongly associated with 
vitamin D levels (p = 1.1 x 10–11) and insufficiency (<30 ng/ml) (OR, 95%CI = 1.28, 
1.16–1.41, p = 1.1 x 10–7).
In conclusion, DHCR7 rs12785878 and GC rs4588, but not CYP2R1 rs10741657, 
are significantly associated with vitamin D levels. When the 3 variants were 
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considered together as GRS, a strong association with vitamin D levels and vitamin 
D insufficiency was observed, thus providing robust evidence that genes involved in 
vitamin D metabolism modulate serum vitamin D in T2D.
INTRODUCTION
The rate of mortality of patients with T2D doubles 
that of non-diabetic individuals of similar age [1], thus 
making diabetes a leading risk factor for all-cause 
mortality worldwide [2]. Therefore, great efforts are 
needed to tackle such tremendous burden, including 
the identification of novel biomarkers and the related 
pathogenic pathways. 
The biologically active form of vitamin D, 
1,25-dihydroxyvitamin D3 plays a central role in a wide 
variety of metabolic pathways. Vitamin D insufficiency, 
affecting as many as 50% healthy adults in developed 
countries, has been linked to autoimmune [3, 4], infectious 
[5], cardiovascular [6], neurodegenerative diseases [7] 
and cancer [8]. Meta-analyses of observational studies 
have consistently found that vitamin D deficiency (and 
insufficiency) is associated with an increased risk of 
cardiovascular mortality and events (i.e. myocardial 
infarction, heart failure and stroke) [9–19] as well as risk 
of T2D [20, 21]. In the specific context of mortality rate 
in T2D, it is worth noticing that low vitamin D levels 
in diabetic patients have been associated with a 2 fold 
increased risk of all-cause and CVD mortality [22].
Although serum levels of vitamin D are to some 
extent under the control of modifiable determinants 
such as dietary intake and synthesis in the skin, classical 
twin studies showed that Vitamin D levels are 50–80% 
heritable [23, 24], thus implying a central role for genetic 
determinants.
Genes affecting vitamin D metabolism are 
candidates for the control of serum vitamin D levels. 
In this respect, three large GWA studies of serum 
25-hydroxyvitamin D reported that variants at three loci 
reached genome-wide significance above all the others 
[25–27]. They were rs12785878 in DHCR7, rs10741657 
in CYP2R1, rs4588 in GC.
DHCR7, which encodes the enzyme 
7-dehydrocholesterol reductase, thereby affecting 
Vitamin D synthesis [28]; CYP2R1, which encodes a 
hepatic microsomal enzyme responsible for vitamin 
D 25-hydroxylation [29]; and GC, which encodes for 
a multifunctional serum glycoprotein that binds and 
transports vitamin D and its metabolites [30].
All genetic association between these three genes 
and Vitamin D levels were observed in the general 
population. Whether these associations are also observed 
among patients with T2D is not know. This lack of 
knowledge is not trivial, given that diabetes per se affects 
vitamin D levels and that vitamin D insufficiency increases 
the rate of mortality in T2D [22]. We tried to give our 
contribution to this subject, by investigating the role of 
variability at DHCR7, CYP2R1 and GC genes, considered 
either individually or in combination, on serum vitamin D 
concentrations in a large and very homogeneous cohort of 
Italian patients with T2D.
RESULTS
The clinical features of all 2163 patients with 
T2D are shown in Table 1. On average, patients in the 
SUMMER study cohort show a mean duration of disease 
of 11.4 years, an acceptable glucose control (HbA1c 
7.3%), and a mean vitamin D level of 23.1 which resulted 
below sufficiency (i.e. < 30 ng/ml).
In all study subjects, genotypes for DHCR7 
rs12785878 T>G (intronic), CYP2R1 rs10741657 G>A 
(5′ UTR) and GC rs4588 G>T (missense Lys214Glu) 
variants as well as serum vitamin D levels were 
determined. We tested the association between DHCR7, 
CYP2R1 and GC genotypes and clinical characteristics 
of study participants including gender, age, weight, 
BMI, waist, HbA1c, T2D duration, blood pressure, total 
cholesterol, HDL and LDL-cholesterol, and circulating 
triglycerides. With the exception of age in DHCR7 
rs12785878 genotypes (being lower in GG individuals), 
no significant difference in any clinical variables was 
observed across genotypes of any SNP (data not shown).
DHCR7 rs12785878 T>G
The rs12785878 SNP at DHCR7 was significantly 
associated with means (95% CIs) vitamin D levels [means: 
23.8 (95%CI = 23.2–24.4), 22.6 (95%CI = 22.0–23.3), 
21.1 (95%CI = 19.9–22.4) ng/ml in TT, TG and GG 
individuals, respectively, p = 3.8 × 10–5] (Table 2).
The observed association was still significant in a 
multivariable model comprising adjustments for gender, 
age, BMI, HbA1c and sampling season (adjusted-p = 
2.1 × 10–5). Similarly, no changes were observed in the 
above-mentioned association when insulin treatment vs. 
oral anti-hyperglycaemic drugs was taken into account as 
a covariate (adjusted-p = 1 × 10–4), in order to address a 
possible confounding effect of diabetes treatment.
CYP2R1 rs10741657 G>A
Though not reaching a formal statistical significance, 
a tendency toward an association was observed between 
the CYP2R1 rs10741657 SNP and mean (95% CIs) 
vitamin D levels [means: 24.7 (95%CI = 23.1–26.4), 23.2 
(95%CI = 22.5–23.9), 22.7 (95%CI = 22.1–23.3) ng/ml in 
AA, AG and GG individuals, respectively, p = 0.11 and 
p = 0.31 in the unadjusted and adjusted model (gender, 
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age, BMI, HbA1c, T2D therapy and sampling season), 
respectively].
GC rs4588 G>T
The GC rs4588 SNP was significantly associated 
with means (95% CIs) vitamin D levels both in unadjusted 
analysis [means: 24.0 (95%CI = 23.4–24.6), 22.3 (95%CI 
= 21.6–22.9), 20.9 (95%CI = 19.6–22.1) ng/ml in GG, GT 
and TT individuals, respectively, p = 5.8 × 10–6] (Table 2) 
and after the inclusion of the possible confounders 
(gender, age, BMI, HbA1c, T2D therapy and sampling 
season) into the model (adjusted-p = 1 × 10–6). 
GRS
Aggregating information from multiple SNPs, each 
with small effects, into a single genetic risk score (GRS) 
has become a useful tool for examining the cumulative 
predictive ability of genetic variation at known loci on 
different disease outcomes and related phenotypes [31]. 
To investigate the combined role on vitamin D levels of 
the three variant considered as a whole, a w-GRS were 
created, as described in Methods. A strong association was 
observed between w-GRS and serum vitamin D both in the 
unadjusted and the adjusted model (beta (SE) = −0.049 
(0.008), p = 1.6 × 10–10, adjusted-p = 1.1 × 10–11). Similar 
results were observed when the unw-GRS was used 
(beta (SE) = −0.049 (0.008); p = 2.2 × 10–9, adjusted-p 
= 1.3 × 10–9); proportions of individuals carrying the 
different number of risk alleles are shown in Table 3. 
In addition, vitamin D levels decreased significantly 
(p = 1.6 × 10–9) across w-GRS quartiles (Figure 1). 
Finally, the w-GRS was strongly associated with vitamin 
D insufficiency, with each score unit increasing the 
probability (OR) of having vitamin D levels <30 ng/ml 
by approximately 30% (OR = 1.28, 95%CI, 1.16–1.40, 
p = 2.6 × 10–7, adjusted-p = 1.1 × 10–7). 
DISCUSSION
The present study, carried out in a large population 
of patients of European ancestry with T2D, is the first 
testing the association between variability in three genes 
involved in vitamin D metabolism and serum vitamin D, a 
biomarker of mortality risk in diabetic patients [22].
We found strong evidence of association between 
low vitamin D levels and SNPs rs12785878 and rs4588, 
harboured by DHCR7 and GC, respectively, while only 
a non-significant trend was observed for rs10741657 at 
CYP2R1. More importantly, when the three SNPs were 
considered in a combined fashion as indicated by a genetic 
risk score, a very strong association with both serum 
Table 1: Clinical and biochemical parameters of study population
Sex (M/F) 1302/861
Age (years) 66.2 ± 9.8 28–94
Weight (kg) 82.9 ± 17.0 39–189
BMI (kg/m2) 29.9 ± 5.4 15–74
Waist (cm) 103.8 ± 13.4 52–230
HbA1c (%/mmol/mol) 7.3 ± 1.5/56.0 ± 15.9 4–15/20–142
T2D duration (years) 11.4 ± 8.8 0–54
TC (mg/dl) 172.2 ± 37.3 69–359
HDL-C (mg/dl) 46.7 ± 12.5 17–104
LDL-C (mg/dl) 97.2 ± 32.4 8–230
TG (mg/dl) 143.4 ± 93.8 30–1576
SBP (mm/Hg) 135.4 ± 15.2 90–200
DBP (mm/Hg) 79.2 ± 9.0 50–130
Vitamina D (ng/ml) 23.1 ± 10.0 7–78
Anti-hypertension drugs yes/no (%) 76/24
Anti-dyslipidemic drugs yes/no (%) 63/37
Anti hyperglycaemic drugs yes/no (%) 91.5/8.5
- On insulin yes/no (%) 28/72 
Values are expressed as means ± standard deviations or rate of subjects, as appropriate in the left column and as ranges in 
the right column. Abbreviations: BMI, body mass index; HbA1c glycosylated hemoglobin SBP, systolic blood pressure; 
DBP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein-cholesterol; 
LDL-C, low density lipoprotein-cholesterol.
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vitamin D and hypovitaminosis was observed. Hence, 
we do have a genetic marker of vitamin D levels, which 
can be used, for example by a Mendelian randomization 
approach [32], to address whether the reported association 
between serum vitamin D and mortality rate [22] in T2D is 
sustained by a cause-effect relationship. 
Our results are consistent with previous studies 
conducted in the general population, reporting that 
DHCR7, CYP2R1 and GC are key loci involved in the 
hereditary control of vitamin D levels [25–27, 33]. SNPs 
in these three genes were therefore chosen because they 
showed the smallest p-values of those reaching genome-
wide significance, and have been replicated in a second 
large study [27], also showing the strongest association 
between these three genes and vitamin D levels.
Given the known role of T2D itself in lowering 
vitamin D levels, our present finding clearly indicates 
that the effect of DHCR7, CYP2R1 and GC variability 
is independent of hyperglycaemia or other intrinsic 
features of diabetes status. Of note, we observed a mean 
difference between genotypes of 4–5 ng/dl in vitamin 
D levels. Although it is reasonable to believe that this 
difference between genotypes in vitamin D level may not 
be clinically relevant, it is conceivable that in diabetic 
Table 2: Vitamin D levels of all participants across DHCR7, CYP2R1 and GC genotypes
Genotypes Vitamin D (ng/ml)
DHCR7 rs12785878 T>G
TT (n = 1099) 23.8 (23.2–24.4)
TG (n = 854) 22.6 (22.0–23.3)
GG (n = 210) 21.1 (19.9–22.4)
Beta-value −0.057 (0.014)
p-value 3.8 × 10–5
adjusted beta-value* −0.058 (0.014)
adjusted p-value* 1 × 10–4
CYP2R1 rs10741657 G>A 
GG (n = 1069) 22.7 (22.1–23.3)
GA (n = 894) 23.2 (22.5–23.9)
AA (n = 200) 24.7 (23.1–26.4)
Beta-value 0.023 (0.014)
p-value 0.11
adjusted beta-value* 0.014 (0.014)
adjusted p-value* 0.31
GC rs4588 G>T
GG (n = 1140) 24.0 (23.4–24.6)
GT (n = 845) 22.3 (21.6–22.9)
TT (n = 178) 20.9 (19.6–22.1)
Beta-value −0.065 (0.014)
p-value 5.8 × 10–6
adjusted beta-value* −0.072 (0.014)
adjusted p-value* 1 × 10–6
Values are expressed as means (95% CIs) and beta values (standard errors). P values < 0.05 are considered significant.
*Adjusted p-values were corrected in multiple linear regression for age, gender, BMI, Hba1c, T2D therapy and seasonality.
Table 3: Proportion of individuals present in each risk-allele subgroup
risk alleles: n subjects: n (%)
0 53 (2.5)
1 317 (14.7)
2 701 (32.4)
3 670 (31)
4 338 (15.6)
5 78 (3.6)
6 6 (0.3)
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subjects, who are already affected by low vitamin D 
levels, a further genetically induced decrease may have in 
the long term detrimental consequences. Only longitudinal 
studies may answer this question.
Strengths of our study are the large, homogeneous 
and clinically well-characterized cohort of patients with 
T2D derived from the SUMMER Study in Diabetes [34]. 
Also, vitamin D levels were determined in all subjects, 
with a single centralized method. Finally the study was 
well powered to detect the previously reported association 
[26] between each genetic variant and serum vitamin D. 
We acknowledge that no information on vitamin D 
supplementation, which might have influenced vitamin D 
levels in our patients, was available. Epidemiological data 
from the ARNO Diabetes Italian registry [35] show that 
only approximately 20% patients with T2D are on vitamin 
supplementation, also including vitamin D. However, 
such a treatment should have occurred randomly across 
genotype groups, thus not interfering with the associations 
that we report here. Another possible limitation of our 
study is that, with the exception of GC rs4588 G>T, 
which results in a Threonine to Lysine amino acid change 
in codon 436 that determines a protein change from 
GC-1 to GC-2 with lower affinity for 25(OH)D [36], no 
functional data are available for the two SNPs in DCHR7 
and CYP2R1 genes. However, with respect to CYP2R1 
gene, a recent analysis of tagging SNPs in the CYP2R1 
locus confirmed the strongest association between Vitamin 
D levels and rs2060793, a tagging SNP in very strong 
LD with our rs10741657 [37], which is therefore highly 
representative of this locus.
In conclusion, this study demonstrates a strong 
independent association between variants in genes 
involved in the metabolism of vitamin D and its circulating 
levels in patients with T2D, establishing for the first time 
the role of these genetic factors in the regulation of vitamin 
D levels also in the clinical setting of type 2 diabetes. 
Based on the present findings, further prospective studies 
may now be designed aimed at addressing the intrinsic 
nature of the association between low serum vitamin D 
and increased mortality rate in T2D [22]. 
METHODS
Study subjects
The first 2163 consecutive study subjects of the 
“Sapienza University Mortality and Morbidity Event Rate 
(SUMMER) study in diabetes” cohort were studied. This 
is an observational, prospective, collaborative study aimed 
at unravelling new molecular predictors of mortality 
and vascular morbidity in patients with T2D [34] (Trial 
registration: ClinicalTrials.gov, NCT02311244; URL: 
https://clinicaltrials.gov/ct2/show/NCT02311244?termZS
UMMER&rankZ5).
Briefly, consecutive patients with T2D of age 
>18 years and European ancestry were recruited from 
the outpatient clinics of 10 Italian centres. All patients 
have undergone a structured interview in order to 
collect information on family history of diabetes and 
cardiovascular disease and on current treatments. All 
subjects have had a complete work-up including clinical 
examination, anthropometric measurements and laboratory 
tests. BMI was calculated as body weight (kg)/height (m2). 
The diagnosis of hypertension was based on the presence 
of elevated systolic (>140 mmHg) and/or diastolic 
Figure 1: Combined effect of risk alleles, as indicated by quartiles of a weighted genotype risk score (w-GRS), on 
Vitamin D levels. Mean Vitamin D levels significantly decreased as a function of the number of risk alleles (p = 1.1 × 10−7). In the x-axis, 
the score range in each quartile is indicated in parenthesis.
Oncotarget34916www.oncotarget.com
(>90 mmHg) blood pressure, and/or the current use of 
antihypertensive medications.
Laboratory determinations
Study populations underwent fasting blood sampling 
to assess glycosylated hemoglobin (HbA1c), total 
cholesterol, HDL-cholesterol, triglycerides, white blood 
cell count, uric acid, serum creatinine and urinary albumin/
creatinine ratio (ACR). Low-density lipoprotein (LDL) 
cholesterol value was obtained using Friedwald formula. 
In addition, measurements of serum 25-hydroxyvitamin 
D levels (by chemiluminescent immunoassay from ARUP 
Laboratory, Salt Lake City, UT, USA) were carried out in 
all study patients. In order to avoid the introduction of a 
bias linked to the different inclination of the sunrays during 
the different seasons of the year, the sampling period was 
taken into account for the statistical analyses [38].
Genotyping assay
The following SNPs have been studied in DNAs 
from all 2163 individuals used for the present study: 
DHCR7 rs12785878 T>G, CYP2R1 rs10741657 G>A, 
GC rs4588 G>T.
Genotyping of SNPs was assayed using the TaqMan 
assays (Applied Biosystems) C_32063037_10 for DHCR7 
rs12785878 T>G, C_2958430_10 for CYP2R1 rs10741657 
G>A and C_8278879_10 for GC rs4588 G>T. The assay 
was carried out on an Eco™ Real-Time PCR System 
by Illumina (San Diego, CA) in a total volume of 10 μl. 
After an initial polymerase activation step at 95° C for 
3 min, amplification was performed using 45 cycles of 
denaturation (95° C for 15 s), annealing and extension 
(60° C for 1 min).
Statistical analysis
Patients’ baseline characteristics were reported as 
mean ± SD and percentages for continuous and categorical 
variables, respectively. Log transformation was used for 
25-OH D levels, that was non-normally distributed. 
Differences between continuous variables across genotype 
classes were evaluated by ANOVA models. Categorical 
variables distribution was compared between groups by χ2 
test. Univariate and multivariate linear regression analysis 
was used to assess the effect of each single SNP (assuming 
an additive genetic model of inheritance) on continuous 
outcome. Multivariable analyses were performed using 
linear regression models adjusting for gender, age, BMI, 
HbA1c and sampling season as binary variable (0 = 
autumn/winter, 1119 subjects and 1 = summer/spring, 1044 
subjects). Results were reported as beta values along with 
their 95% confidence intervals (CIs). A P-value < 0.05 was 
considered as statistically significant. All analyses were 
performed using SPSS version 20.0 (Chicago, IL, USA). 
Power study
In our study the vitamin D was distributed with 
standard deviation equal to 10.4. In the whole sample 
(n = 2163), we had at least 96% power with a type I error 
of 5% and 80% power with a type I error of 1% to detect 
the same effect size of each SNP described by Wang et al. 
[26] in the Framingham Heart Study.
Genetic risk score
An unweighted genotype risk score (unw-GRS) 
was created by summing the number of the risk alleles 
associated with lower vitamin D levels of the 3 SNPs, 
carried by each subject. A weighted genotype risk score 
(w-GRS) was created by summing the weighted effect size 
on serum vitamin D of the 3 SNPs carried by each subject. 
Ethics statement
The study was conducted in accordance with the 
Declaration of Helsinki. The study protocol has been 
approved by the coordinating centre’s Ethic Committee 
and, thereafter, by the Ethics Committee of each centre 
outside the Umberto I “Sapienza” University Hospital, 
in Rome. Written consent was obtained from all subjects 
before the study.
Abbreviations
T2D: type 2 diabetes; BMI: body mass index; 
HbA1c: glycosylated hemoglobin; SBP: systolic blood 
pressure; DBP: diastolic blood pressure; TC: total 
cholesterol; TG: triglycerides; HDL-C: high density 
lipoprotein-cholesterol; LDL-C: low density lipoprotein-
cholesterol; ACR: urinary albumin/creatinine ratio; Cis: 
confidence intervals; unw-GRS: unweighted genotype risk 
score; w-GRS: weighted genotype risk score; DHCR7: 
7-dehydrocholesterol reductase; CYP2R1: Cytochrome 
P450 Family 2 Subfamily R Member 1; GC: Vitamin D 
Binding Protein.
Author contributions 
L. Bertoccini, V. Trischitta, M.G. Baroni designed 
the study; L. Bertoccini, D. Bailetti, R. Buzzetti, M.G. 
Cavallo, E. Cossu, P. D’Angelo, S. De Cosmo, L. Di 
Mauro, F. Leonetti, S. Morano, L. Morviducci, N. Napoli, 
S. Prudente, G. Pugliese participated to the acquisition of 
data and interpretation; L. Bertoccini, V. Trischitta, M.G. 
Baroni, M. Copetti analysed and interpreted the data; L. 
Bertoccini, V. Trischitta, M.G. Baroni drafted the article; 
L. Bertoccini, V. Trischitta, M.G. Baroni, D. Bailetti, 
R. Buzzetti, M.G. Cavallo, E. Cossu, P. D’Angelo, S. 
De Cosmo, L. Di Mauro, F. Leonetti, S. Morano, L. 
Oncotarget34917www.oncotarget.com
Morviducci, N. Napoli, S. Prudente, G. Pugliese revised 
the paper and gave final approval of the version to be 
published.
ACKNOWLEDGMENTS
None.
CONFLICTS OF INTEREST 
No conflicts of interest for all the authors of the 
study.
FUNDING
Financial support was provided by the following 
institutions: “Progetto d’Ateneo 2013” Grant, from 
Sapienza University of Rome (VT); “Progetto d’Ateneo 
2014” Grant, from Sapienza University (MGB); “Assegno 
di Ricerca” from the Italian Society for Diabetes (SID) 
2013 (MGB); “Avvio alla Ricerca 2015–16” Grant, from 
Sapienza University (LB).
REFERENCES
1. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di 
Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal 
KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, 
et al. Diabetes mellitus, fasting glucose, and risk of cause-
specific death. N Engl J Med. 2011; 364:829–841.
2. IDF Diabetes Atlas Update 2017. 2017. http://diabetesatlas.
org/IDF_Diabetes_Atlas_8e_interactive_EN/.
3. Mokry LE, Ross S, Ahmad OS, Forgetta V, Smith GD, 
Goltzman D, Leong A, Greenwood CM, Thanassoulis G, 
Richards JB. Vitamin D and risk of multiple sclerosis: 
a mendelian randomization study. PLoS Med. 2015; 
12:e1001866.
4. Rhead B, Bäärnhielm M, Gianfrancesco M, Mok A, Shao 
X, Quach H, Shen L, Schaefer C, Link J, Gyllenberg 
A, Hedström AK, Olsson T, Hillert J, et al. Mendelian 
randomization shows a causal effect of low vitamin D on 
multiple sclerosis risk. Neurol Genet. 2016; 2:e97.
5. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, 
Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa 
D, Ginde AA, Goodall EC, Grant CC, Griffiths CJ, et al. 
Vitamin D supplementation to prevent acute respiratory 
tract infections: systematic review and meta-analysis of 
individual participant data. BMJ. 2017; 356:i6583.
6. Pilz S, Verheyen N, Grübler MR, Tomaschitz A, März W. 
Vitamin D and cardiovascular disease prevention. Nat Rev 
Cardiol. 2016; 13:404–17.
7. Fernandes de Abreu DA, Eyles D, Féron F. Vitamin D, a 
neuroimmunomodulator: implications for neurodegenerative 
and autoimmune diseases. Psychoneuroendocrinology. 
2009; 34:S265–277.
 8. Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark 
H, Mohr SB, Holick MF. The role of vitamin D in cancer 
prevention. Am J Public Health. 2006; 96:252–261. 
 9. Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, 
Gandini S. VitaminD deficiency and mortality risk in the 
general population: A meta-analysis of prospective cohort 
studies. Am J Clin Nutr. 2012; 95:91–100. 
10. Wang L, Song Y, Manson JE, Pilz S, März W, Michaëlsson 
K, Lundqvist A, Jassal SK, Barrett-Connor E, Zhang 
C, Eaton CB, May HT, Anderson JL, et al. Circulating 
25-hydroxy-vitamin D and risk of cardiovascular disease: a 
meta-analysis of prospective studies. Circ Cardiovasc Qual 
Outcomes. 2012; 5:819–829. 
11. Brøndum-Jacobsen P, Benn M, Jensen GB, Nordestgaard 
BG. 25 hydroxyvitamin d levels and risk of ischemic heart 
disease, myocardial infarction, and early death: population-
based study and meta-analyses of 18 and 17 studies. 
Arterioscler Thromb Vasc Biol. 2012; 32:2794–2802. 
12. Sokol SI, Tsang P, Aggarwal V, Melamed ML, Srinivas VS. 
Vitamin D status and risk of cardiovascular events: lessons 
learned via systematic review and meta-analysis. Cardiol 
Rev. 2011; 19:192–201. 
13. Grandi NC, Breitling LP, Brenner H. Vitamin D and 
cardiovascular disease: systematic review and meta-analysis 
of prospective studies. Prev Med. 2010; 51:228–233.
14. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel 
K, Lichtenstein AH, Lau J, Balk EM. Systematic review: 
Vitamin D and cardiometabolic outcomes. Ann Intern Med. 
2010; 152:307–314. 
15. Tomson J, Emberson J, Hill M, Gordon A, Armitage J, 
Shipley M, Collins R, Clarke R. Vitamin D and risk of death 
from vascular and non-vascular causes in the Whitehall 
study and meta-analyses of 12,000 deaths. Eur Heart J. 
2013; 34:1365–1374. 
16. Fan H, Yu W, Cao H, Li J, Liu B, Wang J, Shao Y, Fan Y, 
Yang J, Zhang Q, Hu X. Meta-analysis of circulating25-
hydroxyvitamin D levels and risk of cardiovascular and all-
cause mortality in elderly population. Int J Cardiol. 2014; 
176:1025–1029. 
17. Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams 
C, Chowdhury S, Kiefte-de-Jong JC, Khan H, Baena CP, 
Prabhakaran D, Hoshen MB, Feldman BS, Pan A, Johnson 
L, et al. Vitamin D and risk of cause specific death: 
systematic review and meta-analysis of observational 
cohort and randomised intervention studies. BMJ. 2014; 
348:g1903. 
18. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin 
D and multiple health outcomes: review of systematic 
reviews and meta-analyses of observational studies and 
randomised trials. BMJ. 2014; 348:g2035. 
19. Schöttker B, Jorde R, Peasey A, Thorand B, Jansen EH, 
Groot L, Streppel M, Gardiner J, Ordóñez-Mena JM, 
Perna L, Wilsgaard T, Rathmann W, Feskens E, et al, and 
Consortium on Health and Ageing: Network of Cohorts in 
Europe and the United States. Vitamin D and mortality: 
Oncotarget34918www.oncotarget.com
meta-analysis of individual participant data from a large 
consortium of cohort studies from Europe and the United 
States. BMJ. 2014; 348:g3656.
20. Afzal S, Brøndum-Jacobsen P, Bojesen SE, Nordestgaard 
BG. Vitamin D concentration, obesity, and risk of diabetes: 
a mendelian randomisation study. Lancet Diabetes 
Endocrinol. 2014; 2:298–306.
21. Lu L, Bennett DA, Millwood IY, Parish S, McCarthy MI, 
Mahajan A, Lin X, Bragg F, Guo Y, Holmes MV, Afzal S, 
Nordestgaard BG, Bian Z, et al. Association of vitamin D 
with risk of type 2 diabetes: A Mendelian randomisation 
study in European and Chinese adults. PLoS Med. 2018; 
15:e1002566.
22. Joergensen C, Gall MA, Schmedes A, Tarnow L, Parving 
HH, Rossing P. Vitamin D levels and mortality in type 2 
diabetes. Diabetes Care. 2010; 33:2238–43. 
23. Karohl C, Su S, Kumari M, Tangpricha V, Veledar E, 
Vaccarino V, Raggi P. Heritability and seasonal variability 
of vitamin D concentrations in male twins. Am J Clin Nutr. 
2010; 92:1393–1398.
24. Orton SM, Morris AP, Herrera BM, Ramagopalan SV, 
Lincoln MR, Chao MJ, Vieth R, Sadovnick AD, Ebers GC. 
Evidence for genetic regulation of vitamin D status in twins 
with multiple sclerosis. Am J Clin Nutr. 2008; 88:441–7. 
25. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, 
McCullough ML, Gallicchio L, Jacobs EJ, Ascherio A, 
Helzlsouer K, Jacobs KB, Li Q, Weinstein SJ, Purdue M, et 
al. Genome-wide association study of circulating vitamin D 
levels. Hum Mol Genet. 2010; 19:2739–45.
26. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs 
JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, 
Peltonen L, Cooper JD, O’Reilly PF, et al. Common genetic 
determinants of vitamin D insufficiency: a genome-wide 
association study. Lancet. 2010; 376:180–88.
27. Jiang X, O’Reilly PF, Aschard H, Hsu YH, Richards 
JB, Dupuis J, Ingelsson E, Karasik D, Pilz S, Berry D, 
Kestenbaum B, Zheng J, Luan J, et al. Genome-wide 
association study in 79,366 European-ancestry individuals 
informs the genetic architecture of 25-hydroxyvitamin D 
levels. Nat Commun. 2018; 9:260. 
28. Tint GS, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, 
Salen G. Defective cholesterol biosynthesis associated with 
the Smith-Lemli-Opitz syndrome. N Engl J Med. 1994; 
330:107–113.
29. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell 
DW. Genetic evidence that the human CYP2R1 enzyme is 
a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A. 
2004; 101:7711–7715.
30. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological 
and clinical aspects of the vitamin D binding protein 
(Gc-globulin) and its polymorphism. Clin Chim Acta. 2006; 
372:33–42.
31. Humphries SE, Yiannakouris N, Talmud PJ. Cardiovascular 
disease risk prediction using genetic information (gene 
scores): is it really informative? Curr Opin Lipidol. 2008; 
19:128–132.
32. Davey Smith G, Hemani G. Mendelian randomization: 
genetic anchors for causal inference in epidemiological 
studies. Hum Mol Genet. 2014; 23:R89–98.
33. Ye Z, Sharp SJ, Burgess S, Scott RA, Imamura 
F, Langenberg C, Wareham NJ, Forouhi NG, and 
InterAct Consortium. Association between circulating 
25-hydroxyvitamin D and incident type 2 diabetes: 
a mendelian randomisation study. Lancet Diabetes 
Endocrinol. 2015; 3:35–42.
34. Barchetta I, Capoccia D, Baroni MG, Buzzetti R, Cavallo 
MG, De Cosmo S, Leonetti F, Leotta S, Morano S, 
Morviducci L, Prudente S, Pugliese G, Trischitta V; 
SUMMER Study in Diabetes Group. The “Sapienza 
University Mortality and Morbidity Event Rate (SUMMER) 
study in diabetes”: Study protocol. Nutr Metab Cardiovasc 
Dis. 2016; 26:103–108.
35. Bruno G, Bonor a E, Miccoli R, Vaccaro O, Rossi E, 
Bernardi D, De Rosa M, Marchesini G, and SID-CINECA 
ARNO Working Group. Quality of diabetes care in Italy: 
information from a large population-based multiregional 
observatory (ARNO diabetes). Diabetes Care. 2012; 35:e64.
36. Engelman CD, Meyers KJ, Iyengar SK, Liu Z, Karki CK, 
Igo RP Jr, Truitt B, Robinson J, Sarto GE, Wallace R, 
Blodi BA, Klein ML, Tinker L, et al. Vitamin D intake and 
season modify the effects of the GC and CYP2R1 genes 
on 25-hydroxyvitamin D concentrations. J Nutr. 2013; 
143:17–26.
37. Cheng J, Belgrader P, Zhou X, Maquat LE. Introns are 
cis effectors of the nonsense-codon-mediated reduction 
in nuclear mRNA abundance. Mol Cell Biol. 1994; 
14:6317–6325.
38. Deleskog A, Hilding A, Brismar K, Hamsten A, Efendic 
S, Östenson CG. Low serum 25-hydroxyvitamin D level 
predicts progression to type 2 diabetes in individuals 
with prediabetes but not with normal glucose tolerance. 
Diabetologia. 2012; 55:1668–1678.
